AnalystsInsight

Tyler Van Buren (TD Cowen): Analyst Track Record and Price‑Target Accuracy

How often Tyler Van Buren’s price targets were reached, how fast, and what the stocks did after each call: a 7‑year backtest of 1,531 ratings, compared with the average Wall Street analyst.

Published Updated 3 min readHow we research

Key takeaways

  • Tyler Van Buren ranks #111 of 1,000 analysts in Exent’s scoring (5.0★).
  • 47.2% of price targets were reached over 7 years, versus 52.4% for the average analyst.
  • Median time to reach a target: 80 days; 48.8% of calls were up 12 months later.
  • Most‑covered stocks: MRNA, GILD, BBIO, ALLO.

Tyler Van Buren’s track record at a glance

Tyler Van Buren of TD Cowen ranks #111 of the 1,000 analysts Exent scores, with a 5.0★ rating and a focus on healthcare. Over a 7‑year lookback, 47.2% of Tyler’s price targets were reached, 5.2 points below the 52.4% average across all analysts.

MetricTyler Van BurenAll analysts
Price‑target hit rate47.2%52.4%
Median days to hit target80 days91 days
Calls up after 12 months48.8%64.0%
Median 12‑month return of calls−1.1%+13.4%
Hit rate, last 2 years56.0%—
Average worst drop after a call−29.7%—
Ratings in the sample1,531—
Stocks covered64—

How fast price targets were reached

Time to reach the targetTyler Van Buren
Under 30 days27.4%
30–90 days27.4%
90–180 days19.8%
Over 180 days25.5%

Share of the targets that were reached, by how long they took. Targets are usually set for 12 months.

Stocks Tyler Van Buren covers most

StockRatings in the sample
MRNA26
GILD25
BBIO20
ALLO15
TVTX15
IMNM13
ARQT13
CRSP13

In the past year Tyler’s ratings were 88% Buy, 12% Hold and 0% Sell.

Recent ratings (shown with a 30-day delay)

DateStockActionRatingPrice target
Sep 14, 2026KRSAInitiated Coverage: BuyBuy$0.00
Aug 31, 2026BRVEInitiated Coverage: BuyBuy$0.00
Aug 26, 2026ORKAReiterated: BuyBuy$0.00
Aug 12, 2026ALLOReiterated: BuyBuy$0.00
Aug 11, 2026ODTXReiterated: BuyBuy$0.00
Aug 11, 2026IMNMReiterated: BuyBuy$0.00
Aug 11, 2026BBIORated: BuyBuy$110.00
Aug 11, 2026CCCCReiterated: BuyBuy$0.00
Aug 11, 2026BHVNReiterated: BuyBuy$30.00
Aug 10, 2026BBIORated: BuyBuy$110.00
Aug 10, 2026OLMAReiterated: BuyBuy$0.00
Aug 10, 2026RVMDReiterated: BuyBuy$0.00
  • Sep 14, 2026
    Stock
    KRSA
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $0.00
  • Aug 31, 2026
    Stock
    BRVE
    Action
    Initiated Coverage: Buy
    Rating
    Buy
    Price target
    $0.00
  • Aug 26, 2026
    Stock
    ORKA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Aug 12, 2026
    Stock
    ALLO
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Aug 11, 2026
    Stock
    ODTX
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Aug 11, 2026
    Stock
    IMNM
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Aug 11, 2026
    Stock
    BBIO
    Action
    Rated: Buy
    Rating
    Buy
    Price target
    $110.00
  • Aug 11, 2026
    Stock
    CCCC
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Aug 11, 2026
    Stock
    BHVN
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $30.00
  • Aug 10, 2026
    Stock
    BBIO
    Action
    Rated: Buy
    Rating
    Buy
    Price target
    $110.00
  • Aug 10, 2026
    Stock
    OLMA
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00
  • Aug 10, 2026
    Stock
    RVMD
    Action
    Reiterated: Buy
    Rating
    Buy
    Price target
    $0.00

Live ratings from Tyler Van Buren and the other top‑ranked analysts, and the stocks where they agree, are in Exent Stocks Radar.

How Exent scores analysts

Exent replays every rating with a price target over a 7‑year lookback: was the target reached, how long it took, and what the stock returned 1, 3, 6 and 12 months after the call. The star rating and rank combine success rate, average return and the number of ratings, so a few lucky calls do not make a top analyst. Statistics as of Jun 24, 2026; ranking updated Oct 19, 2026. How accurate are analyst price targets overall?

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Follow the analysts with the best records

  1. Exent Stocks Radar shows Tyler Van Buren’s live ratings and those of the other top‑ranked analysts, without the 30‑day delay used on this page.
  2. Gems are the stocks where several 4★+ analysts agree: Exent’s shortlist of high‑conviction ideas.
  3. Check any idea against your own portfolio: correlation, concentration and crash exposure before you buy.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

By Exent’s scoring Tyler Van Buren ranks #111 of 1,000 with a 5.0★ rating. 47.2% of price targets were reached over a 7-year lookback (all analysts: 52.4%), and 48.8% of calls were up 12 months later. Past accuracy does not guarantee future accuracy.

Tyler Van Buren’s success rate is 56.3% by the ranking source and 47.2% by Exent’s price-target hit-rate backtest, with a median of 80 days to reach a target.

Tyler Van Buren (TD Cowen) covers 64 stocks, mostly in healthcare. The most frequently rated are MRNA, GILD, BBIO, ALLO, TVTX.

Get the picks Wall Street’s best analysts agree on.

Exent tracks 4,000+ analysts, keeps only the elite few with proven records, and surfaces the Gems where they agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.